Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07160244 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
Secondary endpoints: details revised at 1 of 6 entries
MinorTrial sites reduced: 212 → 206 locations
Trial sites expanded: 207 → 212 locations
v21
MinorStudy sites: 207 to 212v20
MinorTrial sites expanded: 202 → 207 locationsv19
MinorTrial sites expanded: 198 → 202 locationsv18
MinorTrial sites expanded: 179 → 198 locationsv17
NotablePrimary endpoint(s) modified
Study sites: 178 to 179
Secondary endpoints revised (6)
v16
MinorStudy sites: 177 to 178v15
MinorTrial sites expanded: 165 → 177 locationsv14
MinorTrial sites expanded: 162 → 165 locationsv13
MinorTrial sites expanded: 158 → 162 locationsv12
MinorTrial sites expanded: 105 → 158 locationsv11
MinorSite details revised at 1 of 105 sitesv10
MinorStudy sites: 81 to 105v9
MinorStudy sites: 71 to 81v8
MinorStudy sites: 42 to 71v7
MinorStudy sites: 23 to 42v6
MinorStudy sites: 19 to 23v5
MinorStudy sites: 12 to 19v4
MinorStudy sites: 14 to 12v3
MinorStudy sites: 10 to 14v2
MinorStudy First Submitted
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
BEATRIX (group B strEptococcus mATeRnal and Infant VaX study) The purpose of this study is to learn about the safety and how the group B streptococcus (GBS) vaccine works in pregnant women and their babies.
This study is seeking healthy pregnant participants:
* aged 49 or younger who can join.
* between 24 and 36 weeks of gestation ("Gestational age" is a medical term used to describe how far along your pregnancy is)
* had a fetal ultrasound examination performed with no major fetal abnormalities observed
* documented negative for HIV, syphilis and Hepatitis B All participants in this study will receive only 1 shot in an arm. This could either be a group B streptococcus 6-valent polysaccharide conjugate vaccine (GBS6) or placebo. Placebo is an inactive substance used in the study for comparison purposes; in this study, the placebo injection will be saline (saltwater). The pregnant participants may take part in this study for a maximum of 14 months (6 months after delivery) , and their babies for about 12 months after they are born. The pregnant participants will need to visit the research site at least 3 to 4 times with some visits permitted to occur over the telephone.
A subset of infants will be asked to take part in the study for up to 19 months. The subset will receive diphtheria toxoid-containing vaccine and/or pneumococcal vaccine following each country's standard immunization plan and have blood drawn 1 month after completion of the primary and/or toddler (booster) doses.